Published in BMC Cancer on April 11, 2016
Establishment and characterization of a novel highly aggressive gallbladder cancer cell line, TJ-GBC2. Cancer Cell Int (2017) 0.75
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Pancreatic cancer. Lancet (2011) 8.54
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Side population cells in human cancers. Cancer Lett (2008) 2.53
Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery (2013) 2.43
Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res (2008) 1.82
A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol (2001) 1.58
Anaplastic pancreatic cancer: Presentation, surgical management, and outcome. Surgery (2010) 1.49
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res (2012) 1.47
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res (2011) 1.42
Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut (2011) 1.41
Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer (2009) 1.40
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology (2000) 1.37
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol (1998) 1.24
Karyotypic abnormalities in tumours of the pancreas. Br J Cancer (1993) 1.13
Pancreatic adenocarcinoma -- genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer (2006) 1.12
Phenotypical characteristics of undifferentiated carcinoma of the pancreas: a comparison with pancreatic ductal adenocarcinoma and relevance of E-cadherin, alpha catenin and beta catenin expression. Oncol Rep (2001) 1.01
Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testing. Int J Clin Oncol (2010) 0.95
Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer (2011) 0.94
Pleomorphic carcinoma of the pancreas: reappraisal of surgical resection. Am J Gastroenterol (1998) 0.91
Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study. Int J Cancer (2002) 0.90
Clinical outcomes for anaplastic pancreatic cancer: a population-based study. J Am Coll Surg (2012) 0.89